Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluocinonide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 8/20 | 0.98 |
| ▸ | HIF1A | Q16665 | 8/20 | 0.98 |
| ▸ | LMNA | P02545 | 7/20 | 0.98 |
| ▸ | PGR | P06401 | 5/20 | 0.98 |
| ▸ | AR | P10275 | 3/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.98 |
| ▸ | MEN1 | O00255 | 1/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.80 |
| ▸ | MAPT | P10636 | 2/20 | 0.80 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.80 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.65 |
| ▸ | CNR1 | P21554 | 1/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.65 |
| ▸ | USP2 | O75604 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluocinonide SCHEMBL13072779 | 0.99 | HIF1A (1.00) | HIF1ANR3C1LMNAPGRAR | |
| Fluocinonide SCHEMBL2962841 | 0.99 | HIF1A (1.00) | HIF1ANR3C1LMNAPGRAR | |
| Fluocinonide SCHEMBL13072509 | 0.99 | HIF1A (1.00) | HIF1ANR3C1LMNAPGRAR | |
| Fluocinonide SCHEMBL13568069 | 0.99 | HIF1A (1.00) | HIF1ANR3C1LMNAPGRAR | |
| Fluocinonide SCHEMBL13026147 | 0.99 | HIF1A (1.00) | HIF1ANR3C1LMNAPGRAR | |
| Fluocinonide SCHEMBL9338347 | 0.99 | HIF1A (1.00) | HIF1ANR3C1LMNAPGRAR | |
| Fluocinonide SCHEMBL4262 | 0.99 | HIF1A (1.00) | HIF1ANR3C1LMNAPGRAR | |
| Fluocinonide SCHEMBL2800723 | 0.99 | HIF1A (1.00) | HIF1ANR3C1LMNAPGRAR | |
| Fluocinonide SCHEMBL28118986 | 0.98 | NR3C1 (0.98) | HIF1ANR3C1LMNAPGRAR | |
| Fluocinonide SCHEMBL28089918 | 0.96 | NR3C1 (0.94) | HIF1ANR3C1LMNAPGRAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9649382-B2 | Topical bioadhesive formulations | CAMURUS AB (SE) | 2017-05-16 | — | — | US | claimed |
| US-20140186279-A1 | TOPICAL BIOADHESIVE FORMULATIONS | CAMURUS AB (SE) | 2014-07-03 | — | — | US | claimed |
| CN-101563381-A | Adhesive forming compositions and adhesive blends obtained therefrom | MOMENTIVE PERFORMANCE MAT INC (US) | 2009-10-21 | — | — | CN | claimed |
| US-20240100057-A1 | TOPICAL RUXOLITINIB FOR TREATING LICHEN PLANUS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2024-03-28 | — | — | US | disclosed |
| CN-117440814-A | External ruxotinib for treating lichen planus | 因赛特公司 | 2024-01-23 | — | — | CN | disclosed |
| US-20230414620-A1 | TOPICAL RUXOLITINIB FOR TREATING LICHEN PLANUS | INCYTE CORPORATION | 2023-12-28 | — | — | US | disclosed |
| US-20230272347-A1 | Differentiation Method | KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (NL) | 2023-08-31 | — | — | US | disclosed |
| EP-4228614-A1 | IMPROVED DERMATOLOGICAL COMPOSITIONS AND USES THEREOF | Babapour, Reza (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-4221711-A1 | TOPICAL RUXOLITINIB FOR TREATING LICHEN PLANUS | Incyte Corporation (US) | 2023-08-09 | — | — | EP | disclosed |
| US-11591572-B2 | Differentiation method | KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (NL) | 2023-02-28 | — | — | US | disclosed |
| CN-115161257-A | Improved differentiation process | 荷兰皇家科学院 | 2022-10-11 | — | — | CN | disclosed |
| US-20100286107-A1 | Oligomer-Corticosteroid Conjugates | NEKTAR THERAPEUTICS (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100029781-A1 | METHODS FOR PREPARATION OF ANTI-ACNE FORMULATION AND COMPOSITIONS PREPARED THEREBY | ALLERGAN, INC. | 2010-02-04 | — | — | US | disclosed |
| CN-101563381-A | Adhesive forming compositions and adhesive blends obtained therefrom | MOMENTIVE PERFORMANCE MAT INC (US) | 2009-10-21 | — | — | CN | disclosed |
| CN-101534824-A | Aminopyrrolidines as chemokine receptor antagonists | ABBOTT LAB (US) | 2009-09-16 | — | — | CN | disclosed |
| WO-2009045539-A2 | OLIGOMER-CORTICOSTEROID CONJUGATES | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-04-09 | — | — | WO | disclosed |
| CN-100475189-C | Cosmetics composition, preparing method and use thereof | WANG HAILONG FANG ZONGREN ZHAN (CN) | 2009-04-08 | — | — | CN | disclosed |
| CN-101322750-A | Novel use of Cistanche tubulosa extract | XIAOPING ZHANG (CN) | 2008-12-17 | — | — | CN | disclosed |
| CN-1943545-A | Cosmetics composite and its preparing method and use | WANG HAILONG (CN) | 2007-04-11 | — | — | CN | disclosed |
| CN-1215340-A | Composition comprising interleukin-1 inhibitor and controlled release polymer | AMGEN BULDER INC (US) | 1999-04-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140186279-A1 | TOPICAL BIOADHESIVE FORMULATIONS | TTPA, LIPA, DAGLA | NR3C1 2898/4885HIF1A 864/4885LMNA 905/4885 |
| US-20230272347-A1 | Differentiation Method | MYADM, EPCAM, MCL1 | NR3C1 1975/4885HIF1A 718/4885LMNA 4232/4885 |
| US-20240100057-A1 | TOPICAL RUXOLITINIB FOR TREATING LICHEN PLANUS | LPXN, JAK3, JAK1 | NR3C1 601/4885HIF1A 3591/4885LMNA 2723/4885 |
| US-11591572-B2 | Differentiation method | MYADM, EPCAM, MCL1 | NR3C1 1975/4885HIF1A 718/4885LMNA 4232/4885 |
| US-20230414620-A1 | TOPICAL RUXOLITINIB FOR TREATING LICHEN PLANUS | LPXN, JAK3, JAK1 | NR3C1 601/4885HIF1A 3591/4885LMNA 2723/4885 |
| US-20100286107-A1 | Oligomer-Corticosteroid Conjugates | SERPINA6, NR3C2, NR3C1 | NR3C1 3/4885HIF1A 4786/4885LMNA 4428/4885 |
| US-20100029781-A1 | METHODS FOR PREPARATION OF ANTI-ACNE FORMULATION AND COMPOSITIONS PREPARED THEREBY | CUTA, SQLE, HMGCR | NR3C1 1679/4885HIF1A 4462/4885LMNA 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.